Journal article
The Prognostic Effect of Immune Cell Infiltration Depends on Molecular Subtype in Endometrioid Ovarian Carcinomas
Karolin Heinze, Evan S Cairns, Shelby Thornton, Bronwyn Harris, Katy Milne, Marcel Grube, Charlotte Meyer, Anthony N Karnezis, Sian Fereday, Dale W Garsed, Samuel CY Leung, Derek S Chiu, Malak Moubarak, Philipp Harter, Florian Heitz, Jessica N Mcalpine, Anna Defazio, David DL Bowtell, Ellen L Goode, Malcolm Pike Show all
CLINICAL CANCER RESEARCH | AMER ASSOC CANCER RESEARCH | Published : 2023
Abstract
Purpose: Endometrioid ovarian carcinoma (ENOC) is the second most-common type of ovarian carcinoma, comprising 10%-20% of cases. Recently, the study of ENOC has benefitted from comparisons to endometrial carcinomas including defining ENOC with four prognostic molecular subtypes. Each subtype suggests differential mechanisms of progression, although tumorinitiating events remain elusive. There is evidence that the ovarian microenvironment may be critical to early lesion establishment and progression. However, while immune infiltrates have been well studied in high-grade serous ovarian carcinoma, studies in ENOC are limited. Experimental Design: We report on 210 ENOC, with clinical follow-up a..
View full abstractGrants
Awarded by Canadian Institutes of Health Research (Early Career Investigator Grant)
Awarded by VGH & UBC Hospital Foundation
Awarded by National Health and Medical Research Council of Australia (NHMRC)
Awarded by U.S. Army Medical Research and Materiel Command Ovarian Cancer Research Program
Awarded by Victorian Cancer Agency
Funding Acknowledgements
We thank all the study participants who contributed to this study and all the researchers, clinicians, and technical and administrative staff who have made this work possible. We further acknowledge the following financial support: This research was funded in part by the Janet D. Cottrelle Foundation and the Canadian Institutes of Health Research (Early Career Investigator Grant, to M.S. Anglesio). K. Heinze is funded through a research scholarship by the Deutsche Forschungsgesellschaft (HE 8699/1-1). A. Talhouk is funded through a Michael Smith Foundation for Health Research Scholar Award. M.S. Anglesio is funded through a Michael Smith Foundation for Health Research Scholar Award and the Janet D. Cottrelle Foundation Scholars program managed by the BC Cancer Foundation. BC's Gynecological Cancer Research team (OVCARE) receives support through the BC Cancer Foundation and the VGH & UBC Hospital Foundation. S.J. Ramus and D.W. Garsed are supported by National Health and Medical Research Council of Australia (NHMRC) grant APP2009840 (to S.J. Ramus) and grant 1186505 (to D.W. Garsed). This work was supported by the U.S. Army Medical Research and Materiel Command Ovarian Cancer Research Program (award no. W81XWH-16-2-0010). D.W. Garsed is further supported by the U.S. Army Medical Research and Materiel Command Ovarian Cancer Research Program (award no. W81XWH-21-1-0401) and the Victorian Cancer Agency (MCRF22018). E.L. Goode is supported through the following grants: P30-CA015083, P50-CA136939, R01-CA248288. M. Pike was supported in part through the NIH/NCI Support Grant P30 CA008748 (principal investigator: S.M. Vickers) to Memorial Sloan Kettering Cancer Center.